Oncogene · 2022 · 28 citations · 22 references
MedicineCancer BiologyOncologyCarcinogenesisGene ExpressionMolecular OncologyCancer MetabolismHypoxia AdaptationMetabolic ReprogrammingMetabolic Reprogramming In CancerMicrorna-mediated RegulationTumor Suppressor GenesCancer Signaling PathwaysDisease FociMicrorna Function In CancerMicrorna In CancerMicrorna In Cell ProliferationMicrorna Regulation In CancerPolyamine BiosynthesisUrea Cycle Enzyme Regulation
Altered expression of Urea Cycle (UC) enzymes occurs in many tumors, resulting a metabolic hallmark termed as UC dysregulation. Polyamines are synthesized from ornithine, and polyamine synthetic genes are elevated in various tumors. However, the underlying deregulations of UC/ polyamine synthesis in cancer remain elusive. Here, we characterized a hypoxia-induced lncRNA LVBU (lncRNA regulation via BCL6/urea cycle) that is highly expressed in colorectal cancer (CRC) and correlates with poor cancer prognosis. Increased LVBU expression promoted CRC cells proliferation, foci formation and tumorigenesis. Further, LVBU regulates urea cycle and polyamine synthesis through BCL6, a negative regulator of p53. Mechanistically, overexpression of LVBU competitively bound miR-10a/miR-34c to protect BCL6 from miR-10a/34c-mediated degradation, which in turn allows BCL6 to block p53-mediated suppression of genes (arginase1 ARG1, ornithine transcarbamylase OTC, ornithine decarboxylase 1 ODC1) involved in UC/polyamine synthesis. Significantly, ODC1 inhibitor attenuated the growth of patient derived xenografts (PDX) that sustain high LVBU levels. Taken together, elevated LVBU can regulate BCL6-p53 signaling axis for systemic UC/polyamine synthesis reprogramming and confers a predilection toward CRC development. Our data demonstrates that further drug development and clinical evaluation of inhibiting UC/polyamine synthesis are warranted for CRC patients with high expression of LVBU.
22
Molecular landmarks of tumor hypoxia across cancer types
Vinayak Bhandari, Christianne Hoey, Lydia Liu et al. · Nature Genetics · 2019 · 717 citations
Medicine, Cancer Biology, Oncology +16
Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis
Shiran Rabinovich, Lital N. Adler, Keren Yizhak et al. · Nature · 2015 · 392 citations
Medicine, Cancer Biology, Oncology +12
Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures
Joo Sang Lee, Lital N. Adler, Hiren Karathia et al. · Cell · 2018 · 300 citations · Full text